---
schema_version: "secwatch.filing_event.v1"
accession: "0001082554-22-000006"
form_type: "8-K"
ticker: "UTHR"
cik: "0001082554"
company_name: "UNITED THERAPEUTICS Corp"
filed_at: "2022-02-24T23:59:59+00:00"
generated_at: "2026-06-27T04:34:01.750468+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# United Therapeutics FY2021 revenue $1.69B (+14% YoY); Tyvaso DPI decision pushed to May 2022

## Summary
- Full year 2021 revenue $1.69B, up 14% YoY; Q4 revenue $415M, up 8% YoY.
- Net income $475.8M ($10.60 basic GAAP EPS); non-GAAP diluted EPS $15.26.
- Tyvaso net sales $607.5M in 2021, up 26% YoY; Remodulin down 1% to $513.7M.
- Tyvaso DPI NDA extended to May 2022 after FDA requested info on pulmonary safety related to Citizen Petition.
- Patient count reached all-time high; target of 6,000 Tyvaso patients by end of 2022 reaffirmed.

## SEC filing metadata
- accession: 0001082554-22-000006
- form_type: 8-K
- ticker: UTHR
- cik: 0001082554
- company_name: UNITED THERAPEUTICS Corp
- filed_at: 2022-02-24T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1082554/000108255422000006/0001082554-22-000006-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1082554/000108255422000006/uthr-20220224.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001082554-22-000006
- JSON: https://secwatch.observer/filing/0001082554-22-000006.json
- Plain text: https://secwatch.observer/filing/0001082554-22-000006.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.